



Published in final edited form as:

*Cell Stem Cell*. 2016 March 3; 18(3): 382–395. doi:10.1016/j.stem.2016.02.003.

## Bmi1 Is a Key Epigenetic Barrier to Direct Cardiac Reprogramming

Yang Zhou<sup>1,2</sup>, Li Wang<sup>1,2</sup>, Haley Ruth Vaseghi<sup>1,2</sup>, Ziqing Liu<sup>1,2</sup>, Rui Lu<sup>3</sup>, Sahar Alimohamadi<sup>1,2</sup>, Chaoying Yin<sup>1,2</sup>, Ji-Dong Fu<sup>4</sup>, Greg G. Wang<sup>3,5</sup>, Jiandong Liu<sup>1,2</sup>, and Li Qian<sup>1,2,#</sup>

<sup>1</sup>Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599

<sup>2</sup>McAllister Heart Institute, University of North Carolina, Chapel Hill, NC 27599

<sup>3</sup>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599

<sup>4</sup>Department of Medicine, Heart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University, Cleveland, OH 44109

<sup>5</sup>Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599

### SUMMARY

Direct reprogramming of induced cardiomyocytes (iCMs) suffers from low efficiency and requires extensive epigenetic repatterning, although the underlying mechanisms are largely unknown. To address these issues, we screened for epigenetic regulators of iCM reprogramming and found that reducing levels of the polycomb complex gene *Bmi1* significantly enhanced induction of beating iCMs from neonatal and adult mouse fibroblasts. The inhibitory role of *Bmi1* in iCM reprogramming is mediated through direct interactions with regulatory regions of cardiogenic genes, rather than regulation of cell proliferation. Reduced *Bmi1* expression corresponded with increased levels of the active histone mark H3K4me3 and reduced levels of repressive H2AK199ub at cardiogenic loci, and de-repression of cardiogenic gene expression during iCM conversion. Furthermore, *Bmi1* deletion could substitute for *Gata4* during iCM reprogramming. Thus, *Bmi1* acts as a critical epigenetic barrier to iCM production. Bypassing this barrier simplifies iCM generation and increases yield, potentially streamlining iCM production for therapeutic purposes.


### Graphical abstract

Address correspondence to: Dr. Li Qian, 3340B Medical Bioresearch Building, 111 Mason Farm Rd, University of North Carolina, Chapel Hill, Chapel Hill, NC 27599, Phone: 919-962-0340, Fax: 919-966-6012, li\_qian@med.unc.edu.

#### AUTHOR CONTRIBUTIONS

Y.Z. designed and performed experiments, analyzed data and wrote the manuscript. L.W. designed, performed experiments and analyzed data. H.R.V. performed experiments, analyzed data and wrote the manuscript. Z.L., S.A. and C.Y. performed experiments and commented on the manuscript. R.L., J.F. and G.G.W. provided critical reagents and comments on the manuscript. J.L. supervised the work and wrote the manuscript. L. Q. supervised the work, designed the experiments, analyzed data and wrote the manuscript.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## Keywords

cardiac reprogramming; Bmi1; fibroblast; cardiomyocyte; iCM; Gata4; Mef2c; Tbx5; epigenetic; chromatin modification

## INTRODUCTION

The adult mammalian heart has limited regenerative capacity and is thus an important target for novel regenerative approaches to replenish lost cardiomyocytes after cardiac injury (Laflamme and Murry, 2011; Porrello et al., 2011; Ubil et al., 2014; Xin et al., 2013). Cardiac reprogramming that converts fibroblasts to contractile induced cardiomyocytes (iCMs) by overexpression of cardiac lineage specific transcription factors holds great promise as an alternative approach for cardiac regeneration and disease modeling (Addis and Epstein, 2013; Addis et al., 2013; Chen et al., 2012; Fu et al., 2013; Hirai et al., 2013; Ieda et al., 2010; Ifkovits et al., 2014; Jayawardena et al., 2012; Muraoka et al., 2014; Nam et al., 2013; Protze et al., 2012; Qian and Srivastava, 2013; Song et al., 2012; Wada et al., 2013; Wang et al., 2015a; Zhao et al., 2015; Zhou et al., 2015). However, our limited understanding of the molecular mechanism underlying cardiac reprogramming has significantly hindered its potential translational applications.

Epigenetic regulation plays a critical role in shaping and maintaining cellular identities during developmental programming and cellular reprogramming. Recent studies on *in vitro* cardiac differentiation of embryonic stem cells demonstrated that temporal activation of functionally important cardiac genes requires coordinated programmed control of chromatin structure (Paige et al., 2012; Wamstad et al., 2012). Likewise, cellular reprogramming is accompanied by profound changes in the epigenetic landscape (Dhawan et al., 2011; Liang and Zhang, 2012; Luna-Zurita and Bruneau, 2013; Onder et al., 2012; Tursun et al., 2011). This transition in epigenetic status is likely to be involved in suppressing the original cell-type specific signature and establishing and stabilizing a target cell-type specific program

(Apostolou and Hochedlinger, 2013; Buganim et al., 2013; Papp and Plath, 2013). Epigenetic alterations were also observed at both fibroblast- and cardiomyocyte-specific marker genes during iCM reprogramming (Fu et al., 2013; Ieda et al., 2010). However, how these epigenetic transitions are regulated remains elusive. iCM reprogramming, like other types of cellular reprogramming, is an inefficient and slow process, which is at least in part due to multiple epigenetic barriers that have not been identified. It also remains unclear whether iCM reprogramming shares similar epigenetic mechanisms with induced pluripotent stem cell (iPSC) reprogramming or has its own specific barriers.

Here we report the first shRNA-based loss-of-function screen to explore the role of epigenetic factors in iCM reprogramming. Among the identified epigenetic regulators of iCM reprogramming, the polycomb ring finger oncogene *Bmi1* acted as a major epigenetic barrier during the early phase of iCM reprogramming. Genetic and epistasis analyses suggested that the inhibitory effect of *Bmi1* on iCM reprogramming was not completely mediated by its downstream effectors involved in cell proliferation such as *p16<sup>Ink4a</sup>*, *p19<sup>Arf</sup>* and *p53*. Instead, we discovered an uncharacterized role of *Bmi1* in directly binding the regulatory regions of several cardiogenic genes including *Gata4*. Knockdown of *Bmi1* caused de-repression of endogenous *Gata4* and could functionally replace *Gata4* to induce beating iCMs. Thus, our work identifies *Bmi1* as a critical epigenetic barrier at the early stage of iCM reprogramming, and demonstrates that removing early epigenetic barrier is sufficient to generate functional iCMs with fewer transcription factors.

## RESULTS

### Loss-of-function Screen Identified Epigenetic Barriers to and Facilitators of iCM Reprogramming

To identify potential epigenetic regulators of iCM reprogramming, we employed a loss-of-function approach to explore the function of 35 selected components of chromatin modifying or remodeling complexes (Table S1). For each candidate, a pool of shRNAs (4–6 independent shRNA constructs) targeting different regions within the gene was used and knockdown efficiency was validated (Table S1 and Figure S1A). The individual shRNA pools were then transduced into neonatal cardiac fibroblasts isolated by using explant culture method (ExCFs) from a transgenic  $\alpha$ -muscle heavy chain ( $\alpha$ MHC)-GFP reporter mouse (Ieda et al., 2010; Qian et al., 2013) together with retroviruses expressing polycistronic *Mef2c/Gata4/Tbx5* (MGT) (Wang et al., 2015). Upon transduction of MGT, activation of GFP allowed us to follow the emergence of newly induced iCMs. Furthermore, we used cardiac Troponin T (cTnT) as an additional differentiated CM marker to monitor CF to CM fate conversion (Figure 1A). iCM reprogramming efficiency was determined by flow cytometry analysis to quantify the percentage of  $\alpha$ MHC-GFP<sup>+</sup> and cTnT<sup>+</sup> cells (Figure 1A). Although to various degrees, knocking down 11 of the 35 epigenetic regulators reduced reprogramming efficiency (Figure 1B and Table S1). Silencing *inhibitor of growth family member 1* (*Ing1*) or *lysine (K)-specific demethylase 5B* (*Kdm5b/Plu1*) resulted in at least two-fold reduction in the percentages of  $\alpha$ MHC-GFP<sup>+</sup> or cTnT<sup>+</sup> cells (Figure 1B and Table S1). *Ing1* functions as a reader protein of H3K4me3/2, while *Plu1* acts as an H3K4me3/2 demethylase (Table S1). These observations highlight the importance of histone methylation

during iCM reprogramming. On the contrary, loss of Plu1 function has been found to enhance iPSC reprogramming (Kidder et al., 2013), suggesting that this histone modifier might be required for iCM reprogramming while impeding reprogramming to pluripotency.

In addition to the factors that were required for iCM reprogramming, we also identified epigenetic regulators that likely acted as barriers to iCM reprogramming (Figures 1B and 1C). shRNA pools against *K(lysine) acetyltransferase 7 (Kat7/Myst2)*, *K(lysine) acetyltransferase 6A (Kat6a/Myst3)*, *lysine (K)-specific demethylase 5C (Kdm5c/Smcx)* or *inhibitor of growth family member 5 (Ing5)* resulted in a roughly twofold increase in iCM reprogramming efficiency (Figure 1C and Table S1). *Myst2* and *Myst3* belong to MYST family of histone acetyltransferases, whereas *Smcx* functions as an H3K4 demethylase (Table S1). Knockdown of *helicase lymphoid specific (Hells/Lsh/Smarca6)* resulted in a six-fold increase in the percentage of cTnT+ cells (Figures 1B and 1C, Table S1). *Hells* encodes a component of SWI/SNF complex, and targeted deletion of *Hells* leads to a genome-wide loss of DNA methylation and perinatal lethality (Geiman et al., 2001). In conclusion, chromatin regulatory factors involved in various aspects of epigenetic regulation function either as facilitators of or barriers to iCM reprogramming.

### **Bmi1 Acts as A Critical Epigenetic Barrier to iCM Reprogramming**

Among the 35 candidate epigenetic regulators, ablation of *Bmi1*, which encodes a polycomb group protein homologous to *drosophila* protein Posterior Sex Combs (Psc) (van Lohuizen et al., 1991; Van Der Lugt et al., 1994), resulted in the most significant increase in iCM reprogramming efficiency (Figures 1B and 1C, Table S1). Flow analysis and quantification showed that knocking down *Bmi1* led to a ten-fold increase in the percentage of cTnT+ cells (Figures 1B and 1C, Table S1). This significant enhancement of iCM reprogramming efficiency caused by loss of *Bmi1* function is in sharp contrast to its positive role in iPSC reprogramming (Moon et al., 2011; Onder et al., 2012). Thus, we decided to focus on exploring the role of *Bmi1* during fibroblast conversion into iCM. To further determine the effect of *Bmi1* knockdown on iCM reprogramming, we used two individual *Bmi1* shRNAs, along with MGT to convert neonatal ExCFs into iCMs. Consistently, silencing *Bmi1* with these two shRNAs individually resulted in a significant increase in the percentage of  $\alpha$ MHC-GFP+ and cTnT+ cells compared to shNT controls (Figures S1B and S1C). When pooled together, these two shBmi1 oligos had a knockdown efficiency of >90% and increased iCM reprogramming efficiency to an even greater degree than individual shBmi1 oligos (Figures S1C and S1D). For the rest of the study, we used shBmi1-pool (referred to as shBmi1) unless otherwise indicated. shBmi1 treatment not only increased the percentage of iCMs but also resulted in an increased number of iCMs compared to shNT control treatment. We quantified the absolute numbers of  $\alpha$ MHC-GFP+ or cTnT+ iCMs using flow cytometry and observed a significant increase in the numbers of both  $\alpha$ MHC-GFP+ and cTnT+ cells (Figure S1E). Additionally, shBmi1 treated freshly isolated neonatal CFs exhibited a similar increase in reprogramming efficiency and the numbers of  $\alpha$ MHC-GFP+ or cTnT+ cells (Figures 1D and 1E).

We next determined if this increased CF to iCM conversion rate could translate into enhanced structural and functional maturation. We performed immunocytochemistry (ICC)

on shBmi1- and shNT- treated cultures two weeks after infection and found that *Bmi1* knockdown resulted in a significantly increased number of cells expressing sarcomeric  $\alpha$ Actinin and cTnT (Figures 1F–1H). In addition, *Bmi1* knockdown gave rise to an 88.7% increase in the number of  $\alpha$ Actinin+ iCMs that assembled sarcomeres (Figure 1I). More strikingly, we observed twice as many beating iCMs that exhibited periodic calcium oscillation in shBmi1 cultures as in control cultures (Figures 1J–1L, Movies S1–S3). Furthermore, molecular characterization of the *Bmi1* depleted and control cells by examination of the expression of a panel of sarcomere, contractility and ion channel genes revealed higher expression of these functionally important cardiac genes in the *Bmi1* depleted cultures (Figure 1M). Taken together, our data demonstrate that knockdown of *Bmi1* remarkably enhances MGT-mediated iCM reprogramming.

To further assess the repressive function of Bmi1 on cardiac reprogramming, we used the following three commonly used reprogramming methods in conjunction with shBmi1 or shNT to generate iCMs from freshly isolated neonatal CFs: 1) the MGT polycistronic construct (Wang et al., 2015a), 2) separate M+G+T (Ieda et al., 2010) or 3) M+G+T plus Hand2 (M+G+T+H) (Song et al., 2012). Interestingly, we observed the highest percentage of  $\alpha$ MHC-GFP+ or cTnT+ cells by MGT, but the highest absolute number of cTnT+ cells by M+G+T+H regardless of *Bmi1* knockdown (Figures 2A–2F), reflecting varied reprogramming outcomes depending on which marker was used as the readout. Nevertheless, *Bmi1* knockdown uniformly increased iCM percentage across all reprogramming conditions (Figures 2A–2F), and exerted the most influence over the MGT transduced cultures (Figures 2A–2F). The significant increase in reprogramming efficiency observed with *Bmi1* knockdown under all conditions indicates that depletion of *Bmi1* influences cardiac reprogramming mediated by different cocktails and leads to higher reprogramming efficiency (reached to 50% of marker+ iCMs under MGT induction) compared to the corresponding controls.

Furthermore, we validated our findings in multiple cell types of diverse origin, including mouse embryonic fibroblasts (MEFs), neonatal tail tip fibroblasts (TTFs), adult CFs, adult TTFs and CD31+ endothelial cells. Upon *Bmi1* knockdown, all cell types exhibited a significant increase in the percentage and absolute number of cardiac marker positive iCMs 10 days after MGT transduction (Figures 2G–2P). Quantification of flow and ICC analyses also revealed that enhancement of iCM induction varied depending on the cell types assayed (Figures 2G–2P), suggesting potential intrinsic variability of genetic and epigenetic features and cell plasticity among different cell types. To further validate the enhancement of cardiac reprogramming in non-fibroblast CD31+ endothelial cells, we assessed the expression of several sarcomere and ion channel markers, including *Myh6*, *Myl7*, *Actc1*, *Pln*, *Slc8a1*, *Scn5a*, *Cacna1c*, *Ryr2* and *Myl2* and found that these markers were more highly expressed in shBmi1-treated cells, especially the ion channel marker genes (Figure S2A). Thus, *Bmi1* knockdown enhances iCM reprogramming under a variety of conditions and across diverse cell types.

Given the opposing effects of Bmi1 depletion on iCM reprogramming and iPSC reprogramming, we next asked if Bmi1 acted as a general repressor of somatic reprogramming/transdifferentiation or functioned specifically as a repressor of iCM

reprogramming. To this end, we generated induced neurons (iNs) from MEFs by following a recently reported protocol (Xue et al., 2013) with sh*Bmi1* or shNT. The efficiency of iN reprogramming was assessed using ICC of neuron marker--microtubule associated protein 2 (MAP2) (Figure S2B). Although *Bmi1* knockdown appeared to alter the morphology of the MAP2+ iNs (Figure S2B), it did not have any effect on the number of MAP2+ cells (Figure S2C). Further analysis revealed that there was no significant change in the expression levels of additional neuronal markers such as class III  $\beta$ -tubulin (*Tubb3*) and Nestin (*Nes*) with sh*Bmi1* compared to the control (Figure S2D). These results indicate that *Bmi1* does not regulate direct neuron reprogramming but rather acts as a specific repressor of the iCM reprogramming.

### **Bmi1 Functions at the Early Stage of iCM Reprogramming**

Next, we sought to determine the temporal window for silencing *Bmi1* to achieve an enhancement in iCM induction. We performed flow analysis and quantified the percentage of  $\alpha$ MHC-GFP+ and cTnT+ cells generated from sh*Bmi1*- and shNT- treated reprogramming ExCFs at a series of time points. Enhancement in iCM reprogramming efficiency by sh*Bmi1* occurred as early as day 3 (Figures 3A and 3B). Likewise, western blot analysis indicated that *Bmi1* depletion resulted in a significant upregulation of cardiac marker  $\alpha$ MHC-GFP protein expression as early as day 3 (Figure 3C). These observations were further confirmed by the higher expression of a panel of CM marker genes in sh*Bmi1*-treated reprogramming fibroblasts at day 3, suggesting an effect of *Bmi1* knockdown on cardiac fate acquisition at the early stage of reprogramming (Figure 3D). To further define the critical time window for *Bmi1* knockdown, we introduced *Bmi1* shRNAs into neonatal ExCFs at 0, 1, 2, 3 or 5 days after MGT transduction (Figure 3E). Interestingly, we found that iCM reprogramming efficiency as indicated by the percentages of  $\alpha$ MHC-GFP+ or cTnT+ cells was reliably increased only if sh*Bmi1* was introduced within 3 days of MGT infection (Figures 3F and 3G). Depletion of *Bmi1* at 5 days after MGT transduction did not noticeably affect iCM generation (Figures 3F and 3G). Moreover, reasoning that chromatin remodeling is a pre-requisite step to cell fate conversion, we asked if removing the epigenetic barrier by knocking down *Bmi1* prior to the introduction of MGT could lead to a similar enhancement. Fibroblasts were infected with sh*Bmi1*-puro lentiviruses and cultured under puromycin selection for 3 days before MGT transduction (Figure 3H). Flow cytometry analysis showed that sh*Bmi1* treated neonatal ExCFs also had significant higher percentages of  $\alpha$ MHC-GFP+ and cTnT+ cells compared to the controls (Figure 3I). These data suggest that *Bmi1* functions during the early stage of iCM reprogramming, and that knockdown of *Bmi1* must occur within the first 3 days of or prior to MGT introduction to enhance iCM reprogramming.

### **Bmi1 Suppresses iCM Reprogramming Independent of Its Role in Regulating Cell Proliferation**

One of the well-documented functions of *Bmi1* is to regulate cell proliferation and senescence through its downstream effectors p16<sup>Ink4a</sup>, p19<sup>Arf</sup> and p53 (Jacobs et al., 1999; Park et al., 2004). We asked if the enhancement of iCM reprogramming by *Bmi1* knockdown was mediated through an upregulation of p16<sup>Ink4a</sup> (isoform 2 of *Cdkn2a*), p19<sup>Arf</sup> (isoform 1 of *Cdkn2a*) or p53. We first analyzed their expression in control shNT-

and shBmi1-infected reprogramming fibroblasts and found that *Bmi1* depletion indeed resulted in an upregulation of the expression of these target genes during iCM reprogramming (Figure S3A). We then knocked down *Bmi1* and its target genes simultaneously to determine if the increased reprogramming efficiency by *Bmi1* knockdown could be reversed by silencing *Bmi1* target gene expression. qRT-PCR analysis indicated that we knocked down the expression of *Bmi1* target genes by at least 90% (Figure S3B). Interestingly, quantification of flow cytometry analysis showed that the double knockdown cultures exhibited a significant increase in the percentages of  $\alpha$ MHC-GFP<sup>+</sup> and/or cTnT<sup>+</sup> cells compared to the controls (Figure 4A), suggesting that the inhibitory effect of *Bmi1* on iCM reprogramming was unlikely to be completely mediated by these downstream targets.

To further assess the effect of *p53* or *p19<sup>Arf</sup>* ablation on shBmi1-mediated enhancement of iCM reprogramming, we genetically ablated these genes by infecting neonatal ExCFs isolated from *p53* or *p19<sup>Arf</sup>* floxed mice with Ad-Cre-eGFP (Figures 4B–4E, S3C–S3D). This approach allowed us to simultaneously excise the genes and label infected cells with eGFP. Ad-CMV-GFP infection was served as a control. qRT-PCR analysis revealed that *p53* or *p19<sup>Arf</sup>* expression in the Ad-Cre-eGFP infected fibroblasts was significantly reduced compared to that in the Ad-CMV-GFP infected ones (Figure S3C). These cells were then infected with MGT plus shBmi1 or shNT, and analysis of iCM markers was conducted on the GFP positive population of null or wildtype (fl/fl) control fibroblasts (Figure 4B). We observed that reprogramming efficiency of both *p53* null and control CFs was significantly increased by shBmi1 compared to shNT control (Figures 4C and 4D). Likewise, iCM reprogramming efficiency enhanced by *Bmi1* depletion was not suppressed by targeted deletion of *p19<sup>Arf</sup>* (Figure 4E). Interestingly, we found that the expression of *p16<sup>Ink4a</sup>* increased when *p53* or *p19<sup>Arf</sup>* was knocked down and *p19<sup>Arf</sup>* was slightly upregulated upon *p53* or *p16<sup>Ink4a</sup>* depletion (Figure S3E), suggesting the compensatory mechanisms between *p53*, *p16<sup>Ink4a</sup>* and *p19<sup>Arf</sup>*. Therefore, we conducted double and triple knockdowns of *p53*, *p19<sup>Arf</sup>* and *Cdkn2a* to assess their roles in shBmi1-mediated enhancement of cardiac reprogramming. Flow cytometry analysis demonstrated that *Bmi1* depleted cultures exhibited lower but still significant increases in the percentage of  $\alpha$ MHC-GFP<sup>+</sup> or cTnT<sup>+</sup> cells compared to control cultures even when *Cdkn2a* and *p53* were simultaneously silenced (Figure 4F). To further determine if *Bmi1* functions through these genes, we tested if overexpression of each could recapitulate shBmi1 phenotype. Consistently, we found that overexpression of *p53*, *p16<sup>Ink4a</sup>* or *p19<sup>Arf</sup>* did not enhance and sometimes even lowered the percentages of  $\alpha$ MHC-GFP<sup>+</sup> or cTnT<sup>+</sup> cells in MGT-transduced cultures (Figures S3F and S3G). Thus, the well-known downstream targets, *p53*, *p16<sup>Ink4a</sup>* and *p19<sup>Arf</sup>*, are unlikely to be the major downstream mediators of *Bmi1* in cardiac reprogramming.

Based on previous reports that *Bmi1* and its downstream targets are involved in cell proliferation and senescence (Jacobs et al., 1999; Levine, 1997; Ouelle et al., 1995; Sharpless and DePinho, 1999), we sought to determine the requirement of cell proliferation in shBmi1-mediated iCM reprogramming. We used Mitomycin C (MMC), a commonly used inhibitor of cell proliferation, to block CF proliferation 2 days after MGT and shBmi1 or shNT transduction and examined the effect on shBmi1-mediated enhancement of iCM reprogramming (Figure 4G). Interestingly, although MMC treatment inhibited CF

proliferation as evidenced by the lack of Ki67 staining in the nuclei of treated cells (Figure 4I), it did not have any noticeable effect on shBmi1-mediated enhancement of iCM reprogramming (Figure 4H and 4I). Next, we added MMC before the introduction of *Bmi1* shRNAs and treated the cells with 5-ethynyl-2'-deoxyuridine (EdU) to label the proliferating cells upon *Bmi1* knockdown (D2–D10) or 2 days before assaying reprogramming efficiency (D8–D10) (Figure 4J). Consistently, we found that almost all  $\alpha$ MHC-GFP+ iCMs were EdU negative in both shBmi1- and shNT- treated cultures (Figures 4K and 4L). The MMC treatment decreased the reprogramming efficiency; however, depleting *Bmi1* still resulted in an increased percentage of  $\alpha$ MHC-GFP+ iCMs within EdU- cells when compared to the control, reflecting the effect of Bmi1 knockdown in non-proliferating fibroblasts (Figure 4M). These data suggest that Bmi1 functions to suppress iCM generation independently from its role in regulating its downstream effectors involved in cell proliferation.

### Bmi1 Acts as A Repressor through Directly Binding to a Set of Cardiac Loci

As a key component of Polycomb Repressive Complex 1 (PRC1), Bmi1 is essential for PRC1 assembly and together with the catalytic ring finger protein Ring1A and Ring1B (Ring1A/B) mediates monoubiquitination of histone H2A at lysine 119 (H2AK119ub) to repress target gene expression (Cao et al., 2005; Ku et al., 2008; Morey et al., 2015). To gain insights into the mechanism by which Bmi1 modulates iCM reprogramming, we sought to identify direct targets of Bmi1. Interestingly, gene ontology analysis of recently published Bmi1 ChIP-seq data revealed an unexpected enrichment of key cardiac transcription factor genes (Gargiulo et al., 2013) (Figure S4A). This finding prompted us to perform further analysis of this Bmi1 ChIP-seq data as well as publically available global H3K4me3 and H3K27me3 genome mapping data generated with cardiac tissue or cardiac cells (Bernstein et al., 2012; Paige et al., 2012; Wamstad et al., 2012). Through this analysis, we identified strong Bmi1 binding peaks that overlapped with H3K4me3 or H3K27me3 occupied sites at the regulatory regions of cardiogenic genes, including *Gata4*, *Nkx2-5*, *Isl1*, *Pitx2*, *Tbx20*, *Hand2* and *Smad6* (see reviews Olson, 2006; Srivastava, 2006) (Figure 5A and S4B). We therefore postulated that Bmi1 repressed cardiomyocyte fate in non-myocytes by modulating chromatin accessibility of these key cardiac loci. To test this hypothesis, we performed Bmi1 ChIP assay followed by qPCR on MEFs to quantify the enrichment of Bmi1-bound DNA fragments from these cardiogenic gene loci (Figure 5B and S4C). Indeed, we found that Bmi1 bound at distinct regions of the cardiac loci *Gata4*, *Nkx2.5*, *Isl1*, *Pitx2*, *Tbx20* and *Hand2*, but not *Smad6* in fibroblasts. For instance, Bmi1 bound to *Gata4* locus primarily at G3, -3136 ~ -3029 base pairs (bp) upstream from transcription start site (TSS); Bmi1 bound to *Nkx2.5* locus primarily at N6 from -9360 to -9229 bp relative to TSS, which contains Gata factor binding sites and less at N3 from -5842 to -5665 bp relative to TSS where Smad factors bind (Figures 5A and 5B). ChIP-qPCR experiments also revealed that the Bmi1-bound cardiac loci were co-occupied by H2AK119ub, Ring1B and the PRC2 key component Ezh2 (Figures 5C–5E), suggesting a repressive chromatin state of these cardiac loci in fibroblasts.

To test if Bmi1 modulated chromatin status of the cardiogenic genes during the early stage of reprogramming, we performed ChIP-qPCR of H2AK119ub, H3K4me3 and H3K27me3 on *Bmi1* depleted and control MEFs that had been transduced with MGT for three days. The



positive and negative controls for ChIP-qPCR of each mark are shown in Figure S4D. Upon *Bmi1* depletion, H2AK119ub at the cardiogenic loci was completely removed (Figures 5F and S4E), consistent with *Bmi1*'s role in PRC1 assembly to promote monoubiquitination of H2AK119. Additionally, in the absence of *Bmi1*, H3K4me3 levels were moderately increased at the regulatory regions of *Gata4*, *Isl1*, *Pitx2* and *Tbx20* near where *Bmi1* binds (Figures 5G and S4E). Interestingly, the most significant enhancement of H3K4me3 level was detected at *Gata4* locus (Figure 5G). In contrast, H3K27me3 modifications at the same loci were barely affected by *Bmi1* knockdown (Figures 5H and S4E). We only detected a decrease in H3K27me3 modification in the P2 region of *Pitx2* and T3 region of *Tbx20* (Figure 5H). The *Smad6* locus that was not bound by *Bmi1* exhibited low levels of H2AK119ub and H3K27me3. In addition, H3K4me3 levels at *Smad6* were unaltered by loss of *Bmi1* (Figures S4D and S4E, lower panel). Consistent with the increase in the level of H3K4me3 and a major loss of H2AK119ub at the loci, the endogenous mRNA expression of *Gata4*, *Isl1*, *Pitx2* and *Tbx20* were significantly up-regulated by *Bmi1* knockdown during iCM reprogramming (Figures 5I). In contrast, *Bmi1* knockdown did not affect the expression levels of the genes (*Nkx2-5*, *Hand2*) whose loci exhibited reduced H2AK119ub but unaltered H3K4me3 levels (Figures 5I, S4E and S4G). These data suggest that removal of the repressive mark H2AK119ub is not sufficient to induce the expression of all the *Bmi1*-bound cardiogenic genes. The increase in the level of H3K4me3 in addition to a loss of H2AK119ub however is more closely correlated with de-repression of cardiogenic genes expression.

In order to determine if *Bmi1* only repressed the expression of the cardiogenic genes during iCM reprogramming, we re-analyzed the ChIP-seq data (Bernstein et al., 2012; Gargiulo et al., 2013; Paige et al., 2012; Wamstad et al., 2012) and identified *Bmi1* binding peaks that were overlapped with H3K27me3 and H3K4me3 binding sites at other lineage loci (Figures S4H). We carefully selected representative loci encoding regulators of other lineages, including *Zic1* and *Sox2* (ectoderm), *Pax2* and *Sall1* (mesoderm), *Nkx6-1* and *Sox9* (endoderm) to determine the regulation by *Bmi1* during iCM reprogramming (Figure S4H). We found that only two loci (*Pax2* and *Nkx6-1*) had *Bmi1* binding peaks that overlapped with H2AK119ub, Ring1B and Ezh2 binding sites, and upregulated their expression upon *Bmi1* knockdown (Figures S4H-S4K). However, *Bmi1* knockdown did not have any noticeable effect on gene expression of other loci (Figures S4I).

Taken together, our data suggest that *Bmi1* regulates a set of critical cardiogenic factors through directly binding to their regulatory regions to modulate their chromatin status and expression.

### **iCM Reprogramming Using Two Transcription Factors *Mef2c* and *Tbx5***

We were intrigued to find that among the identified targets of *Bmi1*, *Gata4*, one of the transcription factors used for iCM reprogramming (Addis et al., 2013; Fu et al., 2013; Ieda et al., 2010; Ifkovits et al., 2014; Inagawa et al., 2012; Nam et al., 2013; Qian et al., 2012; Song et al., 2012), was most significantly up-regulated in *Bmi1* depleted fibroblasts (Figure 5I). Moreover, *Gata4* can function as a pioneer transcription factor that binds to its target sites on nucleosomes or compacted chromatin (Cirillo et al., 2002). Because removing *Bmi1*

de-repressed endogenous *Gata4* and other cardiogenic genes, we postulated that *Bmi1* depletion could replace *Gata4* in reprogramming fibroblasts into functional iCMs. We systematically evaluated all possible two or one cardiac reprogramming factor combinations for their capacity to reprogram shNT or sh*Bmi1* fibroblasts into iCMs. Flow cytometry analysis revealed that only *Mef2c* in combination with *Tbx5* (M+T) efficiently converted sh*Bmi1* but not the shNT control fibroblasts into iCMs that expressed cardiomyocyte marker genes expression (Figure 6A).

Next, to determine if iCM generation could be achieved with a single vector, we generated 2 polycistronic constructs to express *Mef2c* and *Tbx5* in a single mRNA (MT and TM, Figure 6B). The construct with *Mef2c* at the first position resulted in a higher reprogramming efficiency than the other (Figures 6C and 6D), consistent with our previous finding that stoichiometry of the reprogramming factors influences iCM reprogramming (Wang et al., 2015a). Moreover, the capability of MT plus sh*Bmi1* to reprogram fibroblasts into  $\alpha$ MHC-GFP<sup>+</sup> and/or cTnT<sup>+</sup> cells was abolished upon the depletion of *Gata4* (Figures 6E, S5A and S5B), suggesting that *Gata4* was one of the major downstream effectors of *Bmi1* during iCM reprogramming. Importantly, iCMs generated by MT overexpression with *Bmi1* knockdown not only turned on cardiac marker genes expression, but also assembled sarcomere structures and exhibited calcium oscillation and spontaneous contraction after 2–4 weeks of culture (Figures 6F–6H, Movies S4 and S5), while none of these features were observed with shNT and MT co-infected fibroblasts. Taken together, our results demonstrate that, after removing epigenetic barrier(s) by *Bmi1* depletion, *Mef2c* and *Tbx5* are sufficient to reprogram fibroblasts into functional beating iCMs.

## DISCUSSION

In this study, we performed a functional screen to identify epigenetic regulators of direct cardiac reprogramming. Knocking down a selected set of epigenetic modulators either increased or reduced iCM reprogramming efficiency, highlighting the importance of epigenetic regulation in iCM reprogramming. Specifically, we found that *Bmi1* functioned as a major epigenetic barrier at the early stage of iCM reprogramming. Through a series of epistatic analyses, we demonstrated that the effect of silencing *Bmi1* on cardiac reprogramming was unlikely mediated by its known targets *p16<sup>Ink4a</sup>*, *p19<sup>Arf</sup>* or *p53*. In an effort to explore the underlying mechanism, we found that *Bmi1* directly bound to a set of key cardiogenic loci that are co-occupied by other PRC components. Knockdown of *Bmi1* resulted in a major loss of H2AK119ub and an increase in H3K4me3 levels at these cardiac loci and de-repression of cardiogenic genes expression. This is consistent with previously published findings that H2AK119 monoubiquitination by PRC1 is associated with gene repression (Cao et al., 2005; Wang et al., 2004). It is also possible that knockdown of *Bmi1* de-compacted chromatin and increased DNA accessibility (Abdouh et al., 2016; Eskeland et al., 2010; Francis et al., 2004; Levine et al., 2002; Shao et al., 1999), thereby de-repressing *Gata4* and the other cardiogenic genes. Interestingly, this de-repression of endogenous *Gata4* by *Bmi1* depletion could substitute for exogenous *Gata4* in reprogramming fibroblasts into beating iCMs, demonstrating that removing certain epigenetic barrier(s) could allow for efficient iCM generation with fewer transcription factors.

To the best of our knowledge, the screen we performed in this study represents the first loss-of-function screen to study the role of chromatin-associated proteins in iCM reprogramming. Although our shRNA-based screen was not genome-wide, nor does it cover all epigenetic factors, this study provides proof-of-concept evidence demonstrating the feasibility of an RNAi-mediated functional screen to identify key epigenetic barriers to iCM reprogramming. Given the functional conservation of many epigenetic regulators especially *Bmi1* (98% identity at protein level) between the mouse and human, it is likely that removing similar epigenetic barriers in human fibroblasts will lead to improved generation of human iCMs for clinical studies. Furthermore, the platform and conditions described in this study could be leveraged to develop high throughput large-scale loss-of-function screens. In combination with other approaches such as single cell omics, it is possible in the near future to identify each barrier during iCM reprogramming and to leverage this knowledge to alleviate the roadblocks to enhance and accelerate iCM reprogramming.

In addition to *Bmi1*, we identified a set of epigenetic factors that function as facilitators of or barriers to cardiac reprogramming. These results will stimulate follow-up studies to further interrogate the role of epigenetic factors in iCM reprogramming. Of particular note is the finding that knocking down three MYST histone acetyltransferase family members moderately promoted iCM reprogramming (Figure 1C and Table S1), highlighting the importance of histone acetylation in iCM reprogramming. This finding also suggests possible functional redundancy and compensation among members of epigenetic regulators that belong to the same family. While knocking down *Plu1* enhanced iPSC reprogramming (Kidder et al., 2013), silencing *Plu1* remarkably reduced iCM reprogramming efficiency (Figures 1B, Table S1). Likewise, we observed an opposite effect of *Bmi1* knockdown on iCM versus iPSC reprogramming efficiency and transdifferentiation of neural stem cells (Moon et al., 2011; Onder et al., 2012). Meanwhile, silencing the *Ink4a/Arf* locus, the well-known downstream target repressed by *Bmi1* that functions as a barrier to iPSC and neuronal reprogramming (Li et al., 2009; Price et al., 2014), did not exhibit any noticeable effect on cardiac reprogramming. Our work thus suggests that direct lineage reprogramming, or at least iCM reprogramming, might employ distinct epigenetic regulatory mechanisms from iPSC reprogramming to directly convert one somatic cell type to another.

## EXPERIMENTAL PROCEDURES

### Primary Cell Cultures

Hearts and tail-tips from neonatal pups (day 1.5) or adult mice (4 weeks) were isolated for explant culture. After 7 days, explant cells were separated by magnetic cell sorting (MACS) to obtain Thy1.2+ neonatal or adult CFs and TTFs. CD31+ endothelial cells were derived from explant culture of neonatal hearts by MACS. Fresh CFs were derived from neonatal hearts followed by MACS using anti-Thy1.2 antibody (Miltenyi Biotec) as described previously (Wang et al., 2015a, 2015b). MEFs were prepared as previously described (Jozefczuk et al., 2012). Detailed descriptions of isolation of each cell type are available in the Supplemental Information.

## Viral Packaging and Direct Reprogramming

The protocol of viral packaging is as described in the Supplemental Information. To generate iCMs, fibroblasts or CD31+ endothelial cells were transduced with MGT retroviruses and lentiviruses expressing shRNAs in iCM media (10% FBS of DMEM/M199 (4:1)). At the indicated time points, reprogramming cells were harvested for analyses. For beating assay, freshly isolated CFs were used. After viral infection and 10-days culture in iCM media, cells were changed into StemPro-34 SF medium (SPF34, Gibco) supplemented with GlutaMAX (Gibco), Ascorbic acid (Sigma), VEGF, bFGF and FGF10 (all from R & D Systems). Four to six weeks after viral infection, the number of spontaneously beating cells was counted under an EVOS microscope (40x). Detailed protocols of iCM and iN generation are available in the Supplemental Information.

## Flow Cytometry and ICC

Flow cytometry analysis and ICC were performed as previously described (Wang et al., 2015a, 2015b). The experimental procedure and antibody information are available in the Supplemental Information.

## qPCR, ChIP and Western Blot

Total RNA was isolated with TRIzol (Invitrogen) and reverse-transcribed into cDNA using SuperScript® III Reverse Transcriptase (Invitrogen). qRT-PCR was performed using the ABI ViiA 7 Real-Time PCR system (Applied Biosystems) and the Power SYBR Green PCR Master Mix (Applied Biosystems) or Taqman Gene Expression Master Mix (Taqman, ABI) according to the manufacturer's instructions. The primer sequences and Taqman probes used for qRT-PCR are provided in Supplementary Table S2. ChIP was performed on MEFs according to a previously described protocol (Cai et al., 2013) with minor modification as described in the Supplemental Information. Western blots were performed as described previously (Wang et al., 2015a). Antibody information is available in the Supplemental Information.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We are grateful for the expert technical assistance from the UNC Flow Cytometry Core and UNC Microscopy Core. We thank members of the Qian lab and the Liu lab, Drs. V. Bautch, J. Taylor and C. Mack for helpful discussions and critical reviews of the manuscript. H.V. is supported by a NIH T32 training grant HL069768-14 (PI, Nobuyo Maeda), and a UNC Pathology Sylke Scholarship. R.L. is supported by a postdoc fellowship of Lymphoma Research Foundation. This study was supported by American Heart Association (AHA) Scientist Development Grant 13SDG14580035 to J.D.F., NCI R00 Award CA151683 to G.G.W. (G.G.W. is a Kimmel Scholar of Sidney Kimmel Foundation for Cancer Research), NIH/NHLBI R00 HL109079 grant to J.L., American Heart Association (AHA) Scientist Development Grant 13SDG17060010 and the Ellison Medical Foundation (EMF) New Scholar Grant AG-NS-1064-13 to L.Q.

## References

- Abdouh M, Hanna R, El Hajjar J, Flamier A, Bernier G. The Polycomb Repressive Complex 1 Protein BMI1 Is Required for Constitutive Heterochromatin Formation and Silencing in Mammalian Somatic Cells. *J Biol Chem*. 2016; 291:182–197. [PubMed: 26468281]
- Addis RC, Epstein JA. Induced regeneration--the progress and promise of direct reprogramming for heart repair. *Nat Med*. 2013; 19:829–836. [PubMed: 23836233]
- Addis RC, Ifkovits JL, Pinto F, Kellam LD, Estes P, Rentschler S, Christoforou N, Epstein Ja, Gearhart JD. Optimization of direct fibroblast reprogramming to cardiomyocytes using calcium activity as a functional measure of success. *J Mol Cell Cardiol*. 2013; 60:97–106. [PubMed: 23591016]
- Apostolou E, Hochedlinger K. Chromatin dynamics during cellular reprogramming. 2013
- Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012; 489:57–74. [PubMed: 22955616]
- Buganim Y, Faddah DA, Jaenisch R. Mechanisms and models of somatic cell reprogramming. *Nat Rev Genet*. 2013; 14:427–439. [PubMed: 23681063]
- Cai L, Rothbart SB, Lu R, Xu B, Chen WY, Tripathy A, Rockowitz S, Zheng D, Patel DJ, Allis CD, et al. An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting. *Mol Cell*. 2013; 49:571–582. [PubMed: 23273982]
- Cao R, Tsukada YI, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. *Mol Cell*. 2005; 20:845–854. [PubMed: 16359901]
- Chen JX, Krane M, Deutsch MA, Wang L, Rav-Acha M, Gregoire S, Engels MC, Rajarajan K, Karra R, Abel ED, et al. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. *Circ Res*. 2012; 111:50–55. [PubMed: 22581928]
- Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS. Opening of Compacted Chromatin by Early Developmental Transcription Factors HNF3 (FoxA) and GATA-4. *Mol Cell*. 2002; 9:279–289. [PubMed: 11864602]
- Dhawan S, Georgia S, Tschen Sing, Fan G, Bhushan A. Pancreatic ?? Cell Identity Is Maintained by DNA Methylation-Mediated Repression of Arx. *Dev Cell*. 2011; 20:419–429. [PubMed: 21497756]
- Eskeland R, Leeb M, Grimes GR, Kress C, Boyle S, Sproul D, Gilbert N, Fan Y, Skoultschi AI, Wutz A, et al. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. *Mol Cell*. 2010; 38:452–464. [PubMed: 20471950]
- Francis NJ, Kingston RE, Woodcock CL. Chromatin compaction by a polycomb group protein complex. *Science*. 2004; 306:1574–1577. [PubMed: 15567868]
- Fu JD, Stone NR, Liu L, Spencer CI, Qian L, Hayashi Y, Delgado-Olguin P, Ding S, Bruneau BG, Srivastava D. Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. *Stem Cell Reports*. 2013; 1:235–247. [PubMed: 24319660]
- Gargiulo G, Cesaroni M, Serresi M, deVries N, Hulsman D, Bruggeman S, Lancini C, VanLohuizen M. InVivo RNAi Screen for BMI1 Targets Identifies TGF-??/BMP-ER Stress Pathways as Key Regulators of Neural- and Malignant Glioma-Stem Cell Homeostasis. *Cancer Cell*. 2013; 23:660–676. [PubMed: 23680149]
- Geiman TM, Tessarollo L, Anver MR, Kopp JB, Ward JM, Muegge K. Lsh, a SNF2 family member, is required for normal murine development. *Biochim Biophys Acta*. 2001; 1526:211–220. [PubMed: 11325543]
- Hirai H, Katoku-Kikyo N, Keirstead SA, Kikyo N. Accelerated direct reprogramming of fibroblasts into cardiomyocyte-like cells with the MyoD transactivation domain. *Cardiovasc Res*. 2013; 100:105–113. [PubMed: 23794713]
- Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. *Cell*. 2010; 142:375–386. [PubMed: 20691899]
- Ifkovits JL, Addis RC, Epstein JA, Gearhart JD. Inhibition of TGF $\beta$  signaling increases direct conversion of fibroblasts to induced cardiomyocytes. *PLoS One*. 2014; 9:e89678. [PubMed: 24586958]

- Inagawa K, Miyamoto K, Yamakawa H, Muraoka N, Sadahiro T, Umei T, Wada R, Katsumata Y, Kaneda R, Nakade K, et al. Induction of cardiomyocyte-like cells in infarct hearts by gene transfer of Gata4, Mef2c, and Tbx5. *Circ Res.* 2012; 111:1147–1156. [PubMed: 22931955]
- Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. *Nature.* 1999; 397:164–168. [PubMed: 9923679]
- Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Alan Payne J, Pandya K, Zhang Z, Rosenberg P, Mirosou M, Dzau VJ. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. *Circ Res.* 2012; 110:1465–1473. [PubMed: 22539765]
- Kidder BL, Hu G, Yu ZX, Liu C, Zhao K. Extended self-renewal and accelerated reprogramming in the absence of Kdm5b. *Mol Cell Biol.* 2013; 33:4793–4810. [PubMed: 24100015]
- Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS, Presser A, Nusbaum C, Xie X, Chi AS, et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. *PLoS Genet.* 2008; 4
- Laflamme MA, Murry CE. Heart regeneration. *Nature.* 2011; 473:326–335. [PubMed: 21593865]
- Levine AJ. p53, the Cellular Gatekeeper for Growth and Division. *Cell.* 1997; 88:323–331. [PubMed: 9039259]
- Levine SS, Weiss A, Erdjument-Bromage H, Shao Z, Tempst P, Kingston RE. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. *Mol Cell Biol.* 2002; 22:6070–6078. [PubMed: 12167701]
- Li H, Collado M, Villasante A, Strati K, Ortega S, Can M, Blasco MA, Serrano M. The Ink4 / Arf locus is a barrier for iPS cell reprogramming. 2009; 460:2–7.
- Liang G, Zhang Y. Embryonic stem cell and induced pluripotent stem cell: an epigenetic perspective. *Cell Res.* 2012; 23:49–69. [PubMed: 23247625]
- van Lohuizen M, Verbeek S, Scheljen B, Wientjens E, van der Guidon H, Berns A. Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging. *Cell.* 1991; 65:737–752. [PubMed: 1904008]
- Van Der Lugt NMT, Domen J, Linders K, Van Roon M, Robanus-Maandag E, Te Riele H, Van Der Valk M, Deschamps J, Sofroniew M, Van Lohuizen M, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. *Genes Dev.* 1994; 8:757–769. [PubMed: 7926765]
- Luna-Zurita L, Bruneau BG. Chromatin modulators as facilitating factors in cellular reprogramming. *Curr Opin Genet Dev.* 2013; 23:556–561. [PubMed: 23993229]
- Moon JH, Heo JS, Kim JS, Jun EK, Lee JH, Kim A, Kim J, Whang KY, Kang YK, Yeo S, et al. Reprogramming fibroblasts into induced pluripotent stem cells with Bmi1. *Cell Res.* 2011; 21:1305–1315. [PubMed: 21709693]
- Morey L, Santanach A, Blanco E, Aloia L, Nora EP, Bruneau BG, Di Croce L. Polycomb Regulates Mesoderm Cell Fate-Specification in Embryonic Stem Cells through Activation and Repression Mechanisms. *Cell Stem Cell.* 2015; 17:300–315. [PubMed: 26340528]
- Muraoka N, Yamakawa H, Miyamoto K, Sadahiro T, Umei T, Isomi M, Nakashima H, Akiyama M, Wada R, Inagawa K, et al. MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. *EMBO J.* 2014; 33:1565–1581. [PubMed: 24920580]
- Nam YJ, Song K, Luo X, Daniel E, Lambeth K, West K, Hill Ja, DiMaio JM, Baker La, Bassel-Duby R, et al. Reprogramming of human fibroblasts toward a cardiac fate. *Proc Natl Acad Sci U S A.* 2013; 110:5588–5593. [PubMed: 23487791]
- Olson EN. Gene regulatory networks in the evolution and development of the heart. *Science.* 2006; 313:1922–1927. [PubMed: 17008524]
- Onder TT, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, Cahan P, Marcarci BO, Unternaehrer J, Gupta PB, et al. Chromatin-modifying enzymes as modulators of reprogramming. *Nature.* 2012; 483:598–602. [PubMed: 22388813]
- Ouelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. *Cell.* 1995; 83:993–1000. [PubMed: 8521522]


- Paige SL, Thomas S, Stoick-Cooper CL, Wang H, Maves L, Sandstrom R, Pabon L, Reinecke H, Pratt G, Keller G, et al. A temporal chromatin signature in human embryonic stem cells identifies regulators of cardiac development. *Cell*. 2012; 151:221–232. [PubMed: 22981225]
- Papp B, Plath K. Review Epigenetics of Reprogramming to Induced Pluripotency. *Cell*. 2013; 152:1324–1343. [PubMed: 23498940]
- Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. *J Clin Invest*. 2004; 113:175–179. [PubMed: 14722607]
- Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, Sadek HA. Transient Regenerative Potential of the Neonatal Mouse Heart. *Science* (80- ). 2011; 331:1078–1080.
- Price JD, Park KY, Chen J, Salinas RD, Cho MJ, Kriegstein aR, Lim Da. The Ink4a/Arf Locus Is a Barrier to Direct Neuronal Transdifferentiation. *J Neurosci*. 2014; 34:12560–12567. [PubMed: 25209293]
- Protze S, Khattak S, Poulet C, Lindemann D, Tanaka EM, Ravens U. A new approach to transcription factor screening for reprogramming of fibroblasts to cardiomyocyte-like cells. *J Mol Cell Cardiol*. 2012; 53:323–332. [PubMed: 22575762]
- Qian L, Srivastava D. Direct cardiac reprogramming: from developmental biology to cardiac regeneration. *Circ Res*. 2013; 113:915–921. [PubMed: 24030021]
- Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, Conway SJ, Fu J, Srivastava D. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. *Nature*. 2012; 485:593–598. [PubMed: 22522929]
- Qian L, Berry EC, Fu J, Ieda M, Srivastava D. Reprogramming of mouse fibroblasts into cardiomyocyte-like cells in vitro. *Nat Protoc*. 2013; 8:1204–1215. [PubMed: 23722259]
- Shao Z, Raible F, Mollaaghababa R, Guyon JR, Wu CT, Bender W, Kingston RE. Stabilization of chromatin structure by PRC1, a polycomb complex. *Cell*. 1999; 98:37–46. [PubMed: 10412979]
- Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. *Curr Opin Genet Dev*. 1999; 9:22–30. [PubMed: 10072356]
- Song K, Nam YJ, Luo X, Qi X, Tan W, Huang GN, Acharya A, Smith CL, Tallquist MD, Neilson EG, et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. *Nature*. 2012; 485:599–604. [PubMed: 22660318]
- Srivastava D. Making or Breaking the Heart: From Lineage Determination to Morphogenesis. *Cell*. 2006; 126:1037–1048. [PubMed: 16990131]
- Tursun B, Patel T, Kratsios P, Hobert O. Direct conversion of *C. elegans* germ cells into specific neuron types. *Science*. 2011; 331:304–308. [PubMed: 21148348]
- Ubil E, Duan J, Pillai ICL, Rosa-Garrido M, Wu Y, Bargiacchi F, Lu Y, Stanboully S, Huang J, Rojas M, et al. Mesenchymal-endothelial transition contributes to cardiac neovascularization. *Nature*. 2014; 514:585–590. [PubMed: 25317562]
- Wada R, Muraoka N, Inagawa K, Yamakawa H, Miyamoto K, Sadahiro T, Umei T, Kaneda R, Suzuki T, Kamiya K, et al. Induction of human cardiomyocyte-like cells from fibroblasts by defined factors. *Proc Natl Acad Sci U S A*. 2013; 110:12667–12672. [PubMed: 23861494]
- Wamstad JA, Alexander JM, Truty RM, Shrikumar A, Li F, Eilertson KE, Ding H, Wylie JN, Pico AR, Capra JA, et al. Dynamic and coordinated epigenetic regulation of developmental transitions in the cardiac lineage. *Cell*. 2012; 151:206–220. [PubMed: 22981692]
- Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, Zhang Y. Role of histone H2A ubiquitination in Polycomb silencing. *Nature*. 2004; 431:873–878. [PubMed: 15386022]
- Wang L, Liu Z, Yin C, Asfour H, Chen O, Li Y, Bursac N, Liu J, Qian L. Stoichiometry of Gata4, Mef2c, and Tbx5 influences the efficiency and quality of induced cardiac myocyte reprogramming. *Circ Res*. 2015a; 116:237–244. [PubMed: 25416133]
- Wang L, Liu Z, Yin C, Zhou Y, Liu J, Qian L. Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5. *J Vis Exp*. 2015b:e53426.
- Xin M, Olson EN, Bassel-Duby R. Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair. *Nat Rev Mol Cell Biol*. 2013; 14:529–541. [PubMed: 23839576]

- Xue Y, Ouyang K, Huang J, Zhou Y, Ouyang H, Li H, Wang G, Wu Q, Wei C, Bi Y, et al. Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated MicroRNA circuits. *Cell*. 2013; 152:82–96. [PubMed: 23313552]
- Zhao Y, Londono P, Cao Y, Sharpe EJ, Proenza C, O'Rourke R, Jones KL, Jeong MY, Walker LA, Buttrick PM, et al. High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling. *Nat Commun*. 2015; 6:8243. [PubMed: 26354680]
- Zhou H, Dickson ME, Kim MS, Bassel-Duby R, Olson EN. Akt1/protein kinase B enhances transcriptional reprogramming of fibroblasts to functional cardiomyocytes. *Proc Natl Acad Sci U S A*. 2015 201516237.



### Highlights

- shRNA screen identified *Bmi1* as a major epigenetic barrier to cardiac reprogramming
- *Bmi1* downregulation significantly enhanced iCM generation from mouse fibroblasts
- *Bmi1* directly binds to and suppresses cardiogenic loci
- *Bmi1* depletion can functionally substitute for *Gata4* during iCM conversion



**Figure 1. shRNA Screen Identified Bmi1 as a Critical Epigenetic Modulator of iCM Reprogramming**

(A–C) shRNA screen for identifying epigenetic regulators of iCM reprogramming. (A) Schematic of the shRNA screen. (B) Two-dimensional scatter plot showing fold change (FC) in the percentage of αMHC-GFP+ and cTnT+ cells. (C) Histogram of normalized percentages of αMHC-GFP+ and cTnT+ cells from positive hits. ExCFs, explant cardiac fibroblasts; iCMs, induced cardiomyocytes; shNT, non-targeting shRNA control. (D–E) Representative flow plots (D) and quantification (E) for αMHC-GFP+ and cTnT+ cells 10 days after MGT and shBmi1 or shNT transduction on freshly isolated CFs.


(F–I) Representative immunocytochemistry (ICC) images (F) for  $\alpha$ MHC-GFP (green),  $\alpha$ Actinin (red), and cTnT (magenta) on MGT-transduced freshly isolated CFs infected with shNT or shBmi1, with quantification of the percentage in (G) and the absolute number in (H). High-magnification views of  $\alpha$ Actinin staining show sarcomere structures with quantification in (I). DAPI (blue) was used to stain nuclei. Scale bars, from left to right: 200  $\mu$ m, 200  $\mu$ m, 100  $\mu$ m, 10  $\mu$ m and 200  $\mu$ m.

(J–K) Representative images of spontaneously contracting iCMs (dotted lines) with indicated viral infection four weeks after reprogramming from freshly isolated CFs, corresponding to Supplemental Movies S1 and S2. Quantification of beating cells in one well of 24-well plate is in (K).

(L) Representative images of iCMs exhibiting calcium transient (left panel) with quantification (right panel). iCMs were labeled with Rhod-3 four weeks after MGT and shBmi1 transduction, corresponding to Supplemental Movie S3.

(M) Heatmap of the relative expression of a set of CM and CF marker genes in control CFs, shNT- or shBmi1- infected ExCFs 2 weeks after MGT transduction.

For each experiment,  $n=3\sim 6$  (except  $n=10$  for G, H,  $n=40$  for L), averaged numbers from technical duplicates or triplicates were used for statistics. Error bars indicate mean  $\pm$  SEM, \*  $P < 0.05$ , \*\*  $P < 0.01$ . **See also** Figure 1S.



**Figure 2. Knockdown of Bmi1 Enhanced the Conversion of Diverse Cell Types into iCM by Using Different Cocktails**

(A–F) Representative flow plots with quantification (A–C) and ICC images with quantification (D–F) for αMHC-GFP+ and cTnT+ cells reprogrammed from fresh CFs 10 days after viral infection. DAPI (blue) was used to stain nuclei. Scale bars, 400 μm. (G–P) Representative flow plots with quantification and ICC images with quantification for cardiac marker gene (as indicated) positive cells reprogrammed from MEFs (G and H), neonatal TTFs (I and J), adult CFs (K and L), adult TTFs (M and N) and CD31+ endothelial cells (O and P) 10 days after viral infection. Scale bars, 200 μm. For each experiment, n=3–6 (except n=20 for E and F, n=10 for H,J,L,N,P), averaged numbers from technical


duplicates or triplicates were used for statistics. Error bars indicate mean  $\pm$  SEM, \*  $P < 0.05$ , \*\*  $P < 0.01$ . **See also** Figure S2.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 3. *Bmi1* Functions during the Early Stage of iCM Reprogramming**

(A–B) Histogram showing the percentages of αMHC-GFP+ cells (A) and cTnT+ cells (B) from flow analyses at indicated time points.

(C) Western blot of αMHC-GFP protein expression on ExCFs infected with MGT plus shNT or shBmi1 at indicated days. βActin was used as the loading control.

(D) Fold change (FC) in cardiac marker genes expression levels at reprogramming day 3 between MGT-transduced ExCFs infected with shBmi1 and the ones infected with shNT.


(E) Schematic of experimental design to determine the time window for *Bmi1* knockdown.

(F–G) Quantification of the fold change (FC) in the percentage of αMHC-GFP+ (F) and cTnT+ cells (G) reprogrammed as illustrated in (E). Values were normalized to the corresponding shNT control.

(H) Schematic of experimental design to determine the effect of knocking down *Bmi1* prior to MGT transduction.

(I) Quantification of the fold change (FC) in the percentage of αMHC-GFP+ and cTnT+ cells reprogrammed as illustrated in (H). Values were normalized to corresponding shNT control.

For each experiment,  $n=3\sim6$ , averaged numbers from technical duplicates or triplicates were used for statistics. Error bars indicate mean  $\pm$  SEM, \*  $P < 0.05$ , \*\*  $P < 0.01$ .



**Figure 4. Bmi1 Suppresses iCM Reprogramming Independent of Cell Proliferation**

(A) Quantification of the fold change (FC) in the percentage of the  $\alpha$ MHC-GFP<sup>+</sup> and cTnT<sup>+</sup> cells reprogrammed with indicated shRNAs at day 10. shTubo was used as additional non-targeting control. Values were normalized to the controls.


(B–D) Experiments to determine the effect of targeted deletion of *p53* or *p19<sup>ARF</sup>* on shBmi1-enhanced iCM reprogramming using genetic floxed mice, with schematic in (B), representative flow plots and quantification in (C, D).

(F) Quantification of the fold change (FC) in the percentage of  $\alpha$ MHC-GFP<sup>+</sup> and cTnT<sup>+</sup> cells reprogrammed with indicated shRNA combinations at day 10. Values were normalized to corresponding shNT control.

(G–I) Experiments to determine the effect of Mitomycin C (MMC) treatment on shBmi1-mediated enhancement of iCM reprogramming, with schematic in (G), quantification of flow analyses in (H) and representative ICC pictures of  $\alpha$ Actinin (white),  $\alpha$ MHC-GFP (green) and Ki67 (magenta) in (I). DAPI (blue) indicated nuclei. Scale bars, 200  $\mu$ m. (J–M) The effect of cell proliferation on shBmi1-mediated enhancement of iCM reprogramming. (J) Schematic of the EdU incorporation experiment. (K,L) Representative flow contour plots and quantification without MMC treatment. (M) Quantification of flow analysis for the percentage of  $\alpha$ MHC-GFP<sup>+</sup> cells out of EdU negative cells upon MMC treatment. The starting time point for EdU incorporation is indicated. GFP transduced cells with or without EdU treatment were used as gating controls. UT stands for EdU untreated culture.

For each experiment, n=3~6, averaged numbers from technical duplicates or triplicates were used for statistics. For D and E, each dot represents one experiment from one litter of pups. Error bars indicate mean  $\pm$  SEM, \* P < 0.05, \*\* P < 0.01. **See also** Figure S3.





**Figure 5. Bmi1 Knockdown Resulted in Acquisition of Active Chromatin Status at the Cardiac Loci**


(A) The density of Bmi1, H3K4me3 and H3K27me3 ChIP-seq reads at the indicated gene loci. The gene name initial followed by numbers denotes a series of amplicons that correspond to the binding sites.

(B–E) ChIP–qPCR for Bmi1 (B), H2AK119ub (C), Ring1B (D) or Ezh2 (E) on MEFs at indicated cardiac gene loci. NC (unrelated genomic locus ~22kb upstream to the TSS of *Pitx2* gene) was used as a negative control.

(F–H) ChIP–qPCR for H2AK119ub (F), H3K4me3 (G) and H3K27me3 (H) at cardiac gene loci on MEFs 3 days after transduction of MGT and shRNA targeting *Bmi1* or control.

(I) qRT-PCR of endogenous cardiac gene expression on shNT or shBmi1-infected MGT-expressing MEFs at different time points. Expression at reprogramming D0 was set as 1. RQ stands for relative quantification.

For each experiment, n=3~6, averaged numbers from technical duplicates were used for statistics. Error bars indicate mean  $\pm$  SEM, \* P < 0.05, \*\* P < 0.01. n.s. not significant. **See also** Figure S4.



### Figure 6. Mef2c and Tbx5 Reprogrammed Bmi1 Depleted Fibroblasts into iCMs

(A) Quantification of flow analyses for αMHC-GFP+ or cTnT+ cells on shNT- or shBmi1- infected ExCFs expressing different combinations of Mef2c, Gata4 and Tbx5.

(B) Schematics of the 2 bicistronic vectors encoding Mef2c and Tbx5 in different splicing orders.

(C) Representative flow contour plots of αMHC-GFP+ and cTnT+ cells derived from shNT- or shBmi1- infected ExCFs expressing Mef2c and Tbx5 as indicated.

(D) Quantification of flow data in (C).

(E) Quantification of flow analyses for αMHC-GFP+ (left) and cTnT+ (right) cells on MT-transduced ExCFs co-infected with shRNA targeting *Bmi1*, *Gata4* or non-targeting control shNT or shTubo as indicated.

Data in (A–E) were collected on reprogramming day 10.

(F) Representative ICC image of iCMs labeled by αActinin reprogrammed using MT and shBmi1 at day 14. Inset is a high magnification image of the area highlighted by white rectangle. Left, Scale bar, 100 μm; inset, scale bar, 20 μm.

(G) Representative calcium transients in iCM labeled with Rhod-3 four weeks after MT and shBmi1 transduction on freshly isolated CFs, corresponding to Supplemental Movie S4.

(H) Representative αMHC-GFP+ beating cells (highlighted by white arrows and white dash lines) derived from MT and shBmi1 co-infected fresh CFs four weeks after viral

transduction. The corresponding movie is shown in Supplemental Movie S5. Scale bar, 100  $\mu\text{m}$ .

For each experiment,  $n=3\sim 6$ , averaged numbers from technical duplicates were used for statistics. Error bars indicate mean  $\pm$  SEM, \*  $P < 0.05$ , \*\*  $P < 0.01$ . n.s. not significant. **See also** Figure S5.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript